Vaccines against non-communicable diseases

Current Opinion in Immunology

Volumn 22, Issue 3, 2010, Pages 391-396

  Röhn, Till A ^a   Bachmann, Martin F ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACC 001; AD 01; AD 02; ALZHEIMER DISEASE VACCINE; AMINO TERMINAL AMYLOID BETA PEPTIDE ATTACHED TO CARRIER PROTEIN; AMINO TERMINAL AMYLOID BETA PEPTIDE ATTACHED TO VIRUS LIKE PARTICLE; AMINO TERMINAL AMYLOID BETA PEPTIDE(1-14) CPG OLIGONUCLEOTIDE IMMUNOCOMPLEX; AMYLOID BETA MIMETIC PEPTIDE; AMYLOID BETA PEPTIDE ISCOMATRIX; ANGIOTENSIN I COUPLED TO KEYHOLE LIMPET HEMOCYANIN; ANGIOTENSIN II COUPLED TO VIRUS LIKE PARTICLE; B LYMPHOCYTE VACCINE; CAD 106; INTERLEUKIN 1BETA MUTANT COUPLED TO VIRUS LIKE PARTICLE; PMD 3117; TUMOR NECROSIS FACTOR COUPLED TO KEYHOLE LIMPET HEMOCYANIN; TUMOR NECROSIS FACTOR PEPTIDE COUPLED TO VIRUS LIKE PARTICLE; TUMOR NECROSIS FACTOR WITH INSERTED FOREIGN T HELPER EPITOPE; UB 311; UNCLASSIFIED DRUG; V 950; VACCINE;

ALZHEIMER DISEASE; ANTIBODY TITER; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD PRESSURE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOTHERAPY; INNATE IMMUNITY; MENINGOENCEPHALITIS; MORBIDITY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; T LYMPHOCYTE; VACCINATION; ANIMAL; AUTOIMMUNE DISEASES; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; INFLAMMATION; MOUSE;

ALZHEIMER DISEASE; ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; INFLAMMATION; MICE; VACCINES;

EID: 77953540180     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.02.009     Document Type: Review

References (43)

1. Cooper M.R., Stewart D.C., Kahl F.R., Brown W.M., Cordell A.R. Medicine at the medical center then and now: one hundred years of progress. South Med J 2002, 95:1113-1121.
2. The global burden of disease: 2004 update on World Wide Web URL: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html.
3. Dyer M.R., Renner W.A., Bachmann M.F. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today 2006, 11:1028-1033.
4. Meffre E., Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008, 20:632-638.
5. Bachmann M.F., Dyer M.R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 2004, 3:81-88.
6. Parish I.A., Heath W.R. Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells. Immunol Cell Biol 2008, 86:146-152.
7. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
8. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., Grell S.N., Feldmann M., Elsner H.I., Mouritsen S. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999, 17:666-669.
9. Rohn T.A., Jennings G.T., Hernandez M., Grest P., Beck M., Zou Y., Kopf M., Bachmann M.F. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006, 36:2857-2867.
10. Chackerian B., Lowy D.R., Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001, 108:415-423.
11. Delavallee L., Le Buanec H., Bessis N., Assier E., Denys A., Bizzini B., Zagury D., Boissier M.C. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008, 67:1332-1338.
12. Uyttenhove C., Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006, 36:2868-2874.
13. Jennings G.T., Bachmann M.F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009, 49:303-326.
14. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
15. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008, 31:175-193.
16. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452.
17. Boche D., Nicoll J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol 2008, 18:267-278.
18. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
19. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007, 27:9115-9129.
20. Kayed R., Jackson G.R. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol 2009, 21:359-363.
21. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
22. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., et al. The seventh report of the joint national committee on prevention, detection. Evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
23. Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000, 5(Suppl 1):S31-34.
24. Elliot W.J. Cyclic and circadian variations in cardiovascular events. Am J Hypertens 2001, 14:291S-295S.
25. Pandey R., Quan W.Y., Hong F., Jie S.L. Vaccine for hypertension: modulating the renin-angiotensin system. Int J Cardiol 2009, 134:160-168.
26. Michel J.B., Guettier C., Philippe M., Galen F.X., Corvol P., Menard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A 1987, 84:4346-4350.
27. Michel J.B., Sayah S., Guettier C., Nussberger J., Philippe M., Gonzalez M.F., Carelli C., Galen F.X., Menard J., Corvol P. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990, 81:1899-1910.
28. Brown M.J., Coltart J., Gunewardena K., Ritter J.M., Auton T.R., Glover J.F. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107:167-173.
29. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., Nief V., Schellekens C., Sladko K., Roubicek K., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63-72.
30. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., Volk H.D., Stocker H., Muller P., Jennings G.T., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821-827.
31. Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb on World Wide Web URL: http://www.cytos.com/userfiles/file/Cytos_Press_E_091110.pdf.
32. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008, 20:431-435.
33. Delavallee L., Assier E., Denys A., Falgarone G., Zagury J.F., Muller S., Bessis N., Boissier M.C. Vaccination with cytokines in autoimmune diseases. Ann Med 2008, 40:343-351.
34. Delavallee L., Assier E., Semerano L., Bessis N., Boissier M.C. Emerging applications of anticytokine vaccines. Expert Rev Vaccines 2008, 7:1507-1517.
35. Feldmann M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest 2008, 118:3533-3536.
36. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:578-582.
37. Cytos Biotechnology reports results from a phase I/IIa study with CYT007-TNFQb for the treatment of psoriasis on World Wide Web URL: http://www.cytos.com/doc/070524_Cytos_Press_E.pdf.
38. Montero-Julian F.A., Klein B., Gautherot E., Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995, 85:917-924.
39. Le Buanec H., Delavallee L., Bessis N., Paturance S., Bizzini B., Gallo R., Zagury D., Boissier M.C. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 2006, 103:19442-19447.
40. Neovacs to expand clinical testing of its TNF-α kinoid lead product candidate following positive preliminary findings from a Phase I/II study on World Wide Web URL: http://www.neovacs.fr/pdf_new/TRACKER_PR.pdf.
41. Spohn G., Guler R., Johansen P., Keller I., Jacobs M., Beck M., Rohner F., Bauer M., Dietmeier K., Kundig T.M., et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007, 178:7450-7457.
42. Spohn G., Keller I., Beck M., Grest P., Jennings G.T., Bachmann M.F. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 2008, 38:877-887.
43. Lachmann H.J., Lowe P., Felix S.D., Rordorf C., Leslie K., Madhoo S., Wittkowski H., Bek S., Hartmann N., Bosset S., et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036.